Citius Pharmaceuticals Inc (CTXR) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.28 is considered Undervalued compared with the five-year average of -5.17. The fair price of Citius Pharmaceuticals Inc (CTXR) is between 3.96 to 5.00 according to relative valuation method. Compared to the current price of 0.72 USD , Citius Pharmaceuticals Inc By Undervalued By 81.75%.

Relative Value

Fair Zone

3.96-5.00

Current Price：0.72

81.75%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Citius Pharmaceuticals Inc (CTXR) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Citius Pharmaceuticals Inc (CTXR) has a current Price-to-Book (P/B) ratio of 0.23. Compared to its 3-year average P/B ratio of 1.00, the current P/B ratio is approximately -77.39% higher. Relative to its 5-year average P/B ratio of 1.40, the current P/B ratio is about -83.76% higher. Citius Pharmaceuticals Inc (CTXR) has a Forward Free Cash Flow (FCF) yield of approximately -150.81%. Compared to its 3-year average FCF yield of -74.26%, the current FCF yield is approximately 103.07% lower. Relative to its 5-year average FCF yield of -48.37%, the current FCF yield is about 211.76% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for CTXR competitors is 5.74, providing a benchmark for relative valuation. Citius Pharmaceuticals Inc Corp (CTXR.O) exhibits a P/S ratio of 0.28, which is -95.19% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of CTXR increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of CTXR in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is CTXR currently overvalued or undervalued?

Citius Pharmaceuticals Inc (CTXR) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.28 is considered Undervalued compared with the five-year average of -5.17. The fair price of Citius Pharmaceuticals Inc (CTXR) is between 3.96 to 5.00 according to relative valuation method. Compared to the current price of 0.72 USD, Citius Pharmaceuticals Inc is Undervalued By 81.75%.

What is Citius Pharmaceuticals Inc (CTXR) fair value?

CTXR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Citius Pharmaceuticals Inc (CTXR) is between 3.96 to 5.00 according to relative valuation method.

How does CTXR's valuation metrics compare to the industry average?

The average P/S ratio for CTXR's competitors is 5.74, providing a benchmark for relative valuation. Citius Pharmaceuticals Inc Corp (CTXR) exhibits a P/S ratio of 0.28, which is -95.19% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

What is the current P/B ratio for Citius Pharmaceuticals Inc (CTXR) as of Mar 03 2026?

As of Mar 03 2026, Citius Pharmaceuticals Inc (CTXR) has a P/B ratio of 0.23. This indicates that the market values CTXR at 0.23 times its book value.

What is the current FCF Yield for Citius Pharmaceuticals Inc (CTXR) as of Mar 03 2026?

As of Mar 03 2026, Citius Pharmaceuticals Inc (CTXR) has a FCF Yield of -150.81%. This means that for every dollar of Citius Pharmaceuticals Inc's market capitalization, the company generates -150.81 cents in free cash flow.

What is the current Forward P/E ratio for Citius Pharmaceuticals Inc (CTXR) as of Mar 03 2026?

As of Mar 03 2026, Citius Pharmaceuticals Inc (CTXR) has a Forward P/E ratio of 0.45. This means the market is willing to pay $0.45 for every dollar of Citius Pharmaceuticals Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Citius Pharmaceuticals Inc (CTXR) as of Mar 03 2026?

As of Mar 03 2026, Citius Pharmaceuticals Inc (CTXR) has a Forward P/S ratio of 0.28. This means the market is valuing CTXR at $0.28 for every dollar of expected revenue over the next 12 months.

CTXR Valuation